Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform. Our alphalex™ platform allows small molecule anti-cancer agents to penetrate cell membranes only at the low pH associated with the tumor microenvironment and tumor cells, directly delivering drugs to tumors. It enables intracellular, antigen-independent targeting of tumor cells with existing anti-cancer agents. The enhanced therapeutic index allows combinations of therapies with known synergistic efficacy at doses which were previously thought to be unreachable due to synergistic toxicity. Leveraging the expertise of Cybrexa’s co-founders, our initial application of this platform is focused on DNA Damage Repair (DDR) inhibitors. The company anticipates its lead program, CBX-11 (alphalex™-rucaparib), will enter Phase I in 1Q 2020. We’re passionate about bringing new treatment options to help more cancer patients live longer, more fulfilling lives.